Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Jefferam1on Nov 23, 2016 9:01am

112 Views

Post# 25500895

Quarter financials

Anyone have a guess on when we should see the financial statments for the past quarter? I suspect it should be soon.
My main concern with Antibe is the debt position and lack of cash to fund operations.
Have they successfully acquired funds through any means over the past 6 months?
I think this company and more specifically their current drug ATB-346 has a bright future as long as it can see the light of day.
Anyone else have any thoughts on Antibe financial picture?

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading